Personeni, Nicola

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Pfister, D., Núñez, N. G., Pinyol, R., Govaere, O., Pinter, M., Szydlowska, M., Gupta, R., Qiu, M., Deczkowska, A., Weiner, A., et al. (2021) · Nature

Cancer Immunotherapy and BiomarkersHepatocellular Carcinoma Treatment and Prognosis

Cited by 1,294

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

De Roock, W., Piessevaux, H., De Schutter, J., Janssens, M., De Hertogh, G., Personeni, N., Biesmans, B., Van Laethem, J.-L., Peeters, M., Humblet, Y., et al. (2008) · Annals of Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 827

Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial

Siena, S., Sartore-Bianchi, A., Personeni, N., Pietrantonio, F., Germano, G., Amatu, A., Bonoldi, E., Valtorta, E., Barault, L., Di Nicolantonio, F., et al. (2019) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies

Cited by 15